Abstract:The authors show that monotherapy with immune checkpoint blockers (ICBs) targeting PD‐L1 induces global changes in the tumor microenvironment (TME) in head and neck squamous cell carcinoma (HNSCC) in which PD‐L1 is highly expressed. These results provide mechanistic insights regarding the KEYNOTE‐048 trial that ICB monotherapy can be an effective first‐line therapy in recurrent/metastatic HNSCC. Immune checkpoint blockers (ICBs) targeting programmed cell death protein 1 (PD‐1) have been proven to be an effective first‐line therapy against programmed cell death 1 ligand 1 (PD‐L1; also known as CD274 molecule)‐expressing head and neck squamous cell carcinoma (HNSCC) in recent KEYNOTE‐048 trial. However, associated changes in the tumor microenvironment (TME) and underlying mechanisms remain elusive. Oral tumors in C57/BL6 mice were induced by administering 7,12‐dimethylbenzanthracene into the buccal mucosa. Single‐cell suspension was isolated from tumor tissue; proliferating cells were injected subcutaneously into the left flank of mice to establish Ajou oral cancer (AOC) cell lines. Subsequently, a syngeneic PD‐L1‐expressing HNSCC model was developed by injecting AOC cells into the buccal or tongue area. The model recapitulated human HNSCC molecular features and showed reliable in vivo tumorigenicity with significant PD‐L1 expression. ICB monotherapy induced global changes in the TME, including vascular normalization. Furthermore, the antitumor effect of ICB monotherapy was superior to those of other therapeutic agents, including cisplatin and inhibitors of vascular endothelial growth factor receptor 2 (VEGFR2). The ICB‐induced antitumorigenicity and TME normalization were alleviated by blocking the type I interferon pathway. In summary, ICB monotherapy is sufficient to induce TME normalization in the syngeneic model; the type I interferon pathway is indispensable in realizing the effects of ICBs. Furthermore, these results explain the underlying mechanism of the efficacy of ICB monotherapy against PD‐L1‐expressing HNSCC in the KEYNOTE‐048 trial.

Sharpening Up Tumor Microenvironment to Enhance the Efficacy of Immune Checkpoint Blockade on Head and Neck Cancer Using a CpG-oligodeoxynucleotide

CpG Oligodeoxynucleotides Enhance the Efficacy of Adoptive Cell Transfer Using Tumor Infiltrating Lymphocytes by Modifying the Th1 Polarization and Local Infiltration of Th17 Cells

Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade

Immunostimulatory and Anti-Neoplasm Effects of a Novel Palindrome CpG Oligodeoxynucleotide in Mice

Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer.

Adcances in CpG oligodeoxynucleotides in the cancer immunotherapy

CpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials

Dddt_a_325790 3953..3963

CpG Oligodeoxynucleotide Developed For Activating Primate Immune Responses Promotes Anti-Tumoral Effect Combine With Neo-Antigen Based mRNA Cancer Vaccine

Anti-neoplasm and immuno-modification effect of novel CpG oligodeoxynucleotides in mice

Cpg Oligodeoxynucleotide Developed To Activate Primate Immune Responses Promotes Antitumoral Effects In Combination With A Neoantigen-Based Mrna Cancer Vaccine

Targeting Toll-Like Receptor 9 with CpG Oligodeoxynucleotides Enhances Anti-Tumor Responses of Peripheral Blood Mononuclear Cells from Human Lung Cancer Patients.

Targeting tumor O‐glycosylation modulates cancer–immune‐cell crosstalk and enhances anti‐PD‐1 immunotherapy in head and neck cancer

[Immunostimulatory CpG oligodeoxynucleotides (CpG-ODN) in an orthotopic murine transitional cell carcinoma (TCC) model. Effect on local cytokine expression]

Enhancing Radiosensitivity of Human Pulmonary Adenocarcinoma Cell Line A549 by Cpg Odn1826

Enhanced CTLA‐4 blockade anti‐tumor immunity with APG‐157 combination in a murine head and neck cancer

Gene-guided OX40L Anchoring to Tumor Cells for Synergetic Tumor “Self-Killing” Immunotherapy

Self-assembled nanospheres mediate phototherapy and deliver CpG oligodeoxynucleotides to enhance cancer immunotherapy of breast cancer and melanoma

Immune checkpoint inhibitor monotherapy is sufficient to promote microenvironmental normalization via the type I interferon pathway in PD‐L1‐expressing head and neck cancer

TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells

Nanomaterial-assisted delivery of CpG oligodeoxynucleotides for boosting cancer immunotherapy